



FEATURED

[Abstract](#) [Discussion Forum \(0\)](#)
**Number: Sa1466**
**ESSENTIAL: EFFICACY AND SAFETY OF NON-TRANSPLANT THERAPIES FOR ACUTE LIVER FAILURE SYNDROMES DUE TO INFECTIVE AETIOLOGIES – A REAL-WORLD EXPERIENCE**
**Society:** AGA**Track:** Liver Diseases and Transplantation**Author(s) and Affiliation(s):**
 Ramit Mahajan<sup>1</sup>, Saurabh Singhal<sup>2</sup>, Parshotam Gautam<sup>1</sup>, Rubina K. Mahajan<sup>1</sup>, Arshdeep Singh<sup>1</sup>, Vandana Midha<sup>1</sup>, Ankit Tandon<sup>1</sup>, Yogesh Kumar<sup>1</sup>, Dia Verma<sup>1</sup>, Manisha Khubber<sup>1</sup>, Bhawna Sahota<sup>1</sup>, Ajit Sood<sup>1</sup>

1. Dayanand Medical College and Hospital, Ludhiana, Punjab, India. 2. Aakash Healthcare Private Limited, Dwarka, Delhi, India.

**Background and Aims:** Acute liver failure (ALF) in India primarily stems from infective causes, unlike drug-induced etiologies prevalent in the West. We present a real-world experience of non-transplant therapies like plasma exchange (PLEX) and continuous veno-venous hemofiltration (CVVH) as potential rescue strategies in managing ALF, given the high mortality rate and limited access to orthotopic liver transplantation (OLT) in resource-constrained settings.

**Method:** Retrospective analysis of a prospectively-maintained database of 76 patients with ALF (infective aetiologies) from April 2021 to July 2024 at a single center. Patients were grouped: A) only CVVH, B) PLEX [B1: without CVVH, B2: with CVVH], C) standard medical treatment (SMT). Primary outcome was transplant-free survival at discharge or day 21. We evaluated severity indices: Model for End-Stage Liver Disease (MELD), Sequential Organ Failure Assessment (SOFA), Acute Physiology and Chronic Health Evaluation (APACHE), Acute Liver Failure Study Group (ALFSG) index, and Acute Liver Failure caused by hepatitis A (ALFA) Score. A probability score model predicted optimal treatment modality. Probability calculation:  $1/(1+e^{-score})$ . The model was validated using an independent patient cohort from another center.

**Results:** Groups A, B & C showed similar demographics except presenting creatinine, significantly high in A vs B or C (3.1 vs 1.4 vs 1.4, p=0.001). Among B, creatinine for B2 > B1 (2.9 vs 1.4, p<0.001). ALFSG Score was high for A and B2, lower for B1 and C. Group C had significantly lower bilirubin, ammonia, International Normalized Ratio (INR), and lactate than Groups A and B.

Improvement in creatinine, bilirubin, Aspartate Aminotransferase (AST), and ammonia at 7 days was highest with Group B (B2>B1) > A > C (p<0.05). Survival at 7 days was 78.9% vs 87.8% vs 85.7%. Improvement was seen in 45% vs 71% (81% vs 56%) vs 86% (p=0.031).

Multivariate analysis revealed significant outcome differences for ALFA score, ALFSG index and SOFA. Regression analysis showed probability score for worsening =  $3.2475 + (\hat{\alpha}^{*}1.3688\hat{A} - \text{ALFSG Index}) + (0.0169\hat{A} - \text{SOFA})$ , with 90.9% accuracy. On multinomial logistic regression, individual probability scores: A =  $\hat{\alpha}^{*}1.3337 + (0.4471\hat{A} - \text{ALFSG Index}) + (0.0507\hat{A} - \text{SOFA})$ ; B =  $1.3571 + (\hat{\alpha}^{*}0.0504\hat{A} - \text{ALFSG Index}) + (\hat{\alpha}^{*}0.0937\hat{A} - \text{SOFA})$ ; C =  $\hat{\alpha}^{*}0.0234 + (\hat{\alpha}^{*}0.3967\hat{A} - \text{ALFSG Index}) + (0.0429\hat{A} - \text{SOFA})$ . Models showed 90% sensitivity and 72% accuracy on validation cohort (Hosmer-Lameshow p=0.69). Patients with high creatinine and high SOFA or ALFSG index (unstable) showed better outcomes with CVVH, while those with high ammonia benefited from PLEX.

**Conclusion:** PLEX remains the best treatment for unstable infective ALF patients, with CVVH as a valuable addition for acute kidney injury. The predictive models effectively guide individualized treatment approaches.

**ESSENTIAL: EFFICACY AND SAFETY OF NON-TRANSPLANT THERAPIES FOR ACUTE LIVER FAILURE SYNDROMES DUE TO INFECTIVE AETIOLOGIES – A REAL-WORLD EXPERIENCE**

Dr. Saurabh Singhal

DDW ePoster Library. Singhal S. 05/03/2025; 4154491; Sa1466


[Abstract](#) [Discussion Forum \(0\)](#)
**Number: Sa1466**
**ESSENTIAL: EFFICACY AND SAFETY OF NON-TRANSPLANT THERAPIES FOR ACUTE LIVER FAILURE SYNDROMES DUE TO INFECTIVE AETIOLOGIES – A REAL-WORLD EXPERIENCE**
[READ MORE](#)

## About Us

Digestive Disease Week® (DDW) is the world's premier meeting for physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

## Follow us



2025 © Digestive Disease Week®

[USER TERMS AND CONDITIONS](#) / [PRIVACY POLICY](#)  
(Amended according to GDPR)